Personalized GLP-1 Therapy for Legitimate Weight Management PlexusDx distinguishes between off-label athletic use and clinically appropriate semaglutide therapy for individuals with genuine weight management needs
Patients should review current terms before estimating the next monthly cost
Clinical trials show average weight loss of 15% to 17% of total body weight with semaglutide 2.4 mg over 68 weeks
Dose escalation should be a clinical decision, not a self-directed one
Author contributions HW: Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Software, Validation, Visualization, Writing original draft, Writing review & editing
Improvements in glycaemic control, body mass index, waist circumference and lipid profiles were also observed